TheraRadar
← Back
Data updated: Jul 17, 2026

MILLICENT MFG PR

Pharma
Pharmaceuticals

MILLICENT MFG PR is a pharmaceutical company with 2 FDA-approved products.

2003
Since
2
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
2 Small Molecules

MILLICENT MFG PR's Key Drugs

MILLICENT MFG PR's core commercial portfolio centers on FEMLYV — its most strategically important drugs approved in the last 15 years.

FEMLYV
Women's Health

Pregnancy prevention

Approved 2024

MILLICENT MFG PR's Recent FDA Approvals

MILLICENT MFG PR secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

FEMLYV NDA
2024-07-22
ethinyl estradiol
Pregnancy prevention

MILLICENT MFG PR's Therapeutic Areas

Disease areas where MILLICENT MFG PR has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

MILLICENT MFG PR Pipeline Snapshot

Active clinical trials for MILLICENT MFG PR across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • FEMLYV leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling